Literature DB >> 26040825

Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?

Amy Hsieh1, Ken Pittman1, William K Patterson1, Amanda Townsend1.   

Abstract

Trastuzumab has significantly improved the median survival of patients with HER2-positive breast cancer. In metastatic disease, maintenance trastuzumab is usually given after tumour response has been achieved with the combination of chemotherapy and trastuzumab, with the aim of prolonging time to disease progression. We report a case where a durable complete response (CR) was achieved without maintenance trastuzumab. In the absence of consensus guidelines, it is difficult to recommend which HER2-positive patients with metastatic breast cancer after CR will benefit from withdrawing maintenance trastuzumab therapy and when this could be considered. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26040825      PMCID： PMC4460523          DOI： 10.1136/bcr-2014-207750

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  22 in total

1.  [Long-term survival of a patient with giant liver metastatic breast cancer treated with trastuzumab].

Authors:  Naoya Okada; Yoshiaki Narita; Yoshihide Nanno; Mayu Shimaguchi; Kiyotaka Imamura; Rei Inoue; Toru Nakamura; Minoru Takada; Hiroaki Kato; On Suzuki; Yoshiyasu Ambo; Fumitaka Nakamura; Akihiro Kishida; Nobuichi Kashimura; Osamu Matsunami
Journal:  Gan To Kagaku Ryoho       Date:  2012-09

2.  Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.

Authors:  Filippo Montemurro; Aleix Prat; Valentina Rossi; Giorgio Valabrega; Jeff Sperinde; Caterina Peraldo-Neia; Michela Donadio; Patricia Galván; Anna Sapino; Massimo Aglietta; José Baselga; Maurizio Scaltriti
Journal:  Mol Oncol       Date:  2013-09-13       Impact factor: 6.603

Review 3.  Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.

Authors:  Lajos Pusztai; Francisco J Esteva
Journal:  Cancer Invest       Date:  2006-03       Impact factor: 2.176

4.  18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.

Authors:  Geraldine Gebhart; Cristina Gámez; Eileen Holmes; Javier Robles; Camilo Garcia; Montserrat Cortés; Evandro de Azambuja; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Maria Antonia Coccia-Portugal; Sung-Bae Kim; Peter Vuylsteke; Hervé Cure; Holger Eidtmann; José Baselga; Martine Piccart; Patrick Flamen; Serena Di Cosimo
Journal:  J Nucl Med       Date:  2013-10-03       Impact factor: 10.057

5.  Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.

Authors:  Laurent Arnould; Patrick Arveux; Jerome Couturier; Marion Gelly-Marty; Catherine Loustalot; Francette Ettore; Christine Sagan; Martine Antoine; Frederique Penault-Llorca; Berangere Vasseur; Pierre Fumoleau; Bruno P Coudert
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

6.  HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Authors:  Olivier Humbert; Alexandre Cochet; Jean-Marc Riedinger; Alina Berriolo-Riedinger; Laurent Arnould; Bruno Coudert; Isabelle Desmoulins; Michel Toubeau; Inna Dygai-Cochet; Séverine Guiu; Charles Coutant; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-20       Impact factor: 9.236

7.  High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.

Authors:  Eva-Maria Fuchs; Wolfgang J Köstler; Reinhard Horvat; Gernot Hudelist; Ernst Kubista; Johannes Attems; Christoph C Zielinski; Christian F Singer
Journal:  Int J Cancer       Date:  2014-01-28       Impact factor: 7.396

8.  When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients?

Authors:  Manuela Beda; Umberto Basso; Cristina Ghiotto; Silvio Monfardini
Journal:  Tumori       Date:  2007 Sep-Oct

9.  HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.

Authors:  D Groheux; S Giacchetti; M Hatt; M Marty; L Vercellino; A de Roquancourt; C Cuvier; F Coussy; M Espié; E Hindié
Journal:  Br J Cancer       Date:  2013-08-13       Impact factor: 7.640

10.  Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.

Authors:  D A Yardley; D Tripathy; A M Brufsky; H S Rugo; P A Kaufman; M Mayer; J Magidson; B Yoo; C Quah; M Ulcickas Yood
Journal:  Br J Cancer       Date:  2014-04-17       Impact factor: 7.640
View more
  3 in total

1.  Long-responders to anti-HER2 therapies: A case report and review of the literature.

Authors:  Luca Cantini; Mirco Pistelli; Agnese Savini; Lucia Bastianelli; Arianna Della Mora; Filippo Merloni; Michela Burattini; Rossana Berardi
Journal:  Mol Clin Oncol       Date:  2017-11-08

2.  Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999-2018.

Authors:  Henry G Kaplan; Judith A Malmgren; Boya Guo; Mary K Atwood
Journal:  Breast Cancer Res Treat       Date:  2022-07-22       Impact factor: 4.624

3.  Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series.

Authors:  Haruko Takuwa; Wakako Tsuji; Fumiaki Yotsumoto
Journal:  Int J Surg Case Rep       Date:  2018-10-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.